tetano
Editor, Senior Moderator
PLoS One
. 2023 Jul 31;18(7):e0285349.
doi: 10.1371/journal.pone.0285349. eCollection 2023. Clinical features and outcomes of hospitalised patients with COVID-19 and Parkinsonian disorders: A multicentre UK-based study
Lexy Sorrell[SUP] 1 [/SUP], Valentina Leta[SUP] 2 3 [/SUP], Anton Barnett[SUP] 1 [/SUP], Kara Stevens[SUP] 4 [/SUP], Angela King[SUP] 1 [/SUP], Jemma Inches[SUP] 1 5 [/SUP], Christopher Kobylecki[SUP] 6 7 [/SUP], Richard Walker[SUP] 8 9 [/SUP], K Ray Chaudhuri[SUP] 2 3 [/SUP], Hannah Martin[SUP] 10 [/SUP], Jane Rideout[SUP] 11 [/SUP], J Robert Sneyd[SUP] 11 [/SUP], Sarah Campbell[SUP] 1 [/SUP], Camille Carroll[SUP] 1 5 12 [/SUP]; COVID-19 PD UK study team
Affiliations
Background: Parkinson's disease has been identified as a risk factor for severe Coronavirus disease 2019 (COVID-19) outcomes. However, whether the significant high risk of death from COVID-19 in people with Parkinson's disease is specific to the disease itself or driven by other concomitant and known risk factors such as comorbidities, age, and frailty remains unclear.
Objective: To investigate clinical profiles and outcomes of people with Parkinson's disease and atypical parkinsonian syndromes who tested positive for COVID-19 in the hospital setting in a multicentre UK-based study.
Methods: A retrospective cohort study of Parkinson's disease patients with a positive SARS-CoV-2 test admitted to hospital between February 2020 and July 2021. An online survey was used to collect data from clinical care records, recording patient, Parkinson's disease and COVID-19 characteristics. Associations with time-to-mortality and severe outcomes were analysed using either the Cox proportional hazards model or logistic regression models, as appropriate.
Results: Data from 552 admissions were collected: 365 (66%) male; median (inter-quartile range) age 80 (74-85) years. The 34-day all-cause mortality rate was 38.4%; male sex, increased age and frailty, Parkinson's dementia syndrome, requirement for respiratory support and no vaccination were associated with increased mortality risk. Community-acquired COVID-19 and co-morbid chronic neurological disorder were associated with increased odds of requiring respiratory support. Hospital-acquired COVID-19 and delirium were associated with requiring an increase in care level post-discharge.
Conclusions: This first, multicentre, UK-based study on people with Parkinson's disease or atypical parkinsonian syndromes, hospitalised with COVID-19, adds and expands previous findings on clinical profiles and outcomes in this population.
. 2023 Jul 31;18(7):e0285349.
doi: 10.1371/journal.pone.0285349. eCollection 2023. Clinical features and outcomes of hospitalised patients with COVID-19 and Parkinsonian disorders: A multicentre UK-based study
Lexy Sorrell[SUP] 1 [/SUP], Valentina Leta[SUP] 2 3 [/SUP], Anton Barnett[SUP] 1 [/SUP], Kara Stevens[SUP] 4 [/SUP], Angela King[SUP] 1 [/SUP], Jemma Inches[SUP] 1 5 [/SUP], Christopher Kobylecki[SUP] 6 7 [/SUP], Richard Walker[SUP] 8 9 [/SUP], K Ray Chaudhuri[SUP] 2 3 [/SUP], Hannah Martin[SUP] 10 [/SUP], Jane Rideout[SUP] 11 [/SUP], J Robert Sneyd[SUP] 11 [/SUP], Sarah Campbell[SUP] 1 [/SUP], Camille Carroll[SUP] 1 5 12 [/SUP]; COVID-19 PD UK study team
Affiliations
- PMID: 37523365
- DOI: 10.1371/journal.pone.0285349
Background: Parkinson's disease has been identified as a risk factor for severe Coronavirus disease 2019 (COVID-19) outcomes. However, whether the significant high risk of death from COVID-19 in people with Parkinson's disease is specific to the disease itself or driven by other concomitant and known risk factors such as comorbidities, age, and frailty remains unclear.
Objective: To investigate clinical profiles and outcomes of people with Parkinson's disease and atypical parkinsonian syndromes who tested positive for COVID-19 in the hospital setting in a multicentre UK-based study.
Methods: A retrospective cohort study of Parkinson's disease patients with a positive SARS-CoV-2 test admitted to hospital between February 2020 and July 2021. An online survey was used to collect data from clinical care records, recording patient, Parkinson's disease and COVID-19 characteristics. Associations with time-to-mortality and severe outcomes were analysed using either the Cox proportional hazards model or logistic regression models, as appropriate.
Results: Data from 552 admissions were collected: 365 (66%) male; median (inter-quartile range) age 80 (74-85) years. The 34-day all-cause mortality rate was 38.4%; male sex, increased age and frailty, Parkinson's dementia syndrome, requirement for respiratory support and no vaccination were associated with increased mortality risk. Community-acquired COVID-19 and co-morbid chronic neurological disorder were associated with increased odds of requiring respiratory support. Hospital-acquired COVID-19 and delirium were associated with requiring an increase in care level post-discharge.
Conclusions: This first, multicentre, UK-based study on people with Parkinson's disease or atypical parkinsonian syndromes, hospitalised with COVID-19, adds and expands previous findings on clinical profiles and outcomes in this population.